Supplementary Figure S2 from A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
Hui Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin et autres
0 citations
Kate Fluck
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
9Publications signalées
109Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Glioma Diagnosis and TreatmentColorectal Cancer Surgical TreatmentsAngiogenesis and VEGF in CancerMonoclonal and Polyclonal Antibodies ResearchColorectal Cancer Treatments and Studies
Les publications récentes
Supplementary Table S2 from A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
Hui Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin et autres
0 citations
Supplementary Table S1 from A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
Hui Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin et autres
0 citations
Data from A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
Hui Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin et autres
0 citations
Supplementary Figure S1 from A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
Hui Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin et autres
0 citations
Supplementary Table S3 from A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
Hui Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin et autres
0 citations
A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma
Hui Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin et autres
au, jp (code pays fourni par la source)
0 citations
Clinical Cancer Research
Abstract CT101: Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma
Hui Gan, Lawrence Cher, Po Inglis, Zarnie Lwin et autres
au, us (code pays fourni par la source)
0 citations
Cancer Research
Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
Andrew Weickhardt, Timothy Price, Geoff Chong, Val Gebski et autres
au (code pays fourni par la source)
110 citations
Journal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.